Case Western Reserve University's Technology Transfer Office has entered a worldwide exclusive licensing agreement with TRACON Pharmaceuticals of San Diego, Calif., to develop Methoxyamine, a new cancer therapeutic that reverses cancer cell resistance to chemotherapy. Methoxyamine is a "first in class" drug that targets a specific DNA repair pathway.
TRACON Pharmaceuticals is an emerging biotechnology company focused on identifying, developing and commercializing targeted therapies for cancer and angiogenesis. TRACON's management team couples their ability to execute with their extensive knowledge of oncology drug development and first generation targeted therapies, enabling them to advance the development of next generation cancer therapies.
Methoxyamine was developed by University Hospitals Case Medical Center researchers Stanton Gerson, M.D., director of the National Cancer Institute-designated Case Comprehensive Cancer Center and University Hospitals Ireland Cancer Center, and Lili Lui, Ph.D., assistant professor of medicine in the department of hematology and oncology at the Case School of Medicine. They were the first to show the therapeutic potential of Methoxyamine as an anti-cancer drug in combination with other agents.
"We are very excited about the potential of this new drug. The promise of overcoming a major mechanism of drug resistance in cancer is terrific news for many patients. We see potential applications in patients with brain cancers, melanoma, lung cancer and leukemias and perhaps other cancers," said Gerson.
Under the licensing agreement, TRACON will develop and manage clinical trials of Methoxyamine. "We are excited to be able to develop Methoxyamine. Chemotherapy represents the most commonly used class of agents to treat cancer patients. Unfortunately, resistance of cancer cells to chemotherapy prevents many patients from benefiting. Methoxyamine's unique ability to reverse resistance to chemotherapy could improve the lives of the many patients treated with chemotherapy each year," noted Charles Theuer, M.D., Ph.D., president and CEO of TRACON.
Research for this new therapeutic evolved from the researchers' project in the National Institutes of Health Rapid Access to Interventional Development (RAID) program that provides researchers resources and support needed for the development of new therapeutics. The NIH RAID program focuses on a subset of small molecules, including new agents that improve the activity of established chemotherapeutics.
The patented therapy, which has been licensed to TRACON, has been studied most intensively in combination with the approved chemotherapeutic Temozolomide. Methoxyamine prevents cancer cells from repairing DNA damage caused by chemotherapy, according to Steve Tan, a senior licensing manager in Case's Tech Transfer Office.
According to Michael Haag, director of biomedical licensing in Case's Tech Transfer Office, Methoxyamine could improve the anti-cancer activity of many chemotherapeutic agents, including those used for solid tumors and hematologic malignancies.
TRACON was established in 2005, with a focus on targeted cancer therapies (TaRgeted Approach and Control in Oncology) .
Charles P. Theuer, M.D., Ph.D., serves as president and CEO. Theuer joined TRACON after developing pharmaceuticals for TargeGen Inc, a company that develops small molecule kinase inhibitors in oncology, ophthalmology and cardiovascular disease, and Pfizer where he led the clinical development of Sutent® in kidney cancer.
About University Hospitals of Cleveland: Founded in 1866, University Hospitals of Cleveland is a 947-bed tertiary medical center specializing in adult/pediatric medical and surgical specialties. UHC is also the primary affiliate of Case Western Reserve University. Together, they form the largest center for biomedical research in the State of Ohio. As the research arm of University Hospitals of Cleveland, the Center for Clinical Research focuses on translational research, taking fundamental advances in biomedical research and applying them to improvements in healthcare. This is achieved through a balanced approach involving federal-funded research, sponsored research agreements with the pharmaceutical, biotechnology and medical device industries, and a century-long partnership with Case Western Reserve University. The Center for Clinical Research is designed to aggressively translate fundamental advances in scientific knowledge into advances in the clinical medicine by establishing new alliances with the pharmaceutical, biotechnology and medical device industries.
University Hospitals Ireland Cancer Center and Case Western Reserve University partner as the National Cancer Institute (NCI) designated Case Comprehensive Cancer Center. This means that the Ireland Cancer Center has met standards of excellence established by NCI for research and clinical care. The Ireland Cancer Center provides a full spectrum of state-of-the-art cancer care and services; High quality, integrated research activities from basic to clinical to prevention and control research; Information services to the public; Education and training for health research and health care professionals; and Various other outreach activities which impact on the communities and region that the Cancer Center services.
Case Western Reserve University is committed to the free exchange of ideas, reasoned debate and intellectual dialogue. Speakers and scholars with a diversity of opinions and perspectives are invited to the campus to provide the community with important points of view, some of which may be deemed controversial. The views and opinions of those invited to speak on the campus do not necessarily reflect the views of the university administration or any other segment of the university community.